<![CDATA[FDA Extends Review Period for Orca-T in Hematologic Malignancies ]]>

Summary: The FDA needs three more months to review a promising new blood cancer treatment called Orca-T, pushing the decision date to July 6, 2026. The delay is just for reviewing manufacturing paperwork, not because of safety issues. In fact, studies show Orca-T has a massive 78% survival rate without severe immune reactions, compared to just 38% for standard treatments. The medical world is eagerly waiting for this breakthrough to finally get the green light.

For more details, see cancernetwork at cancernetwork.com/view/fda-extends-review-period-for-orca-t-in-hematologic-malignancies (opens in new tab)